top stories

A $1B-plus drug stum­bles in­to an­oth­er big PhI­II set­back -- this time flunk­ing fu­til­i­ty test -- as FDA hold re­mains in ef­fect for Ipsen

23 hours ago
R&D

Deer­field vaults to the top of cell and gene ther­a­py CD­MO game with $1.1B fa­cil­i­ty at Philadel­phi­a's newest bio­phar­ma ...

22 hours ago
Cell/Gene Tx
Outsourcing

2019 a 'trans­for­ma­tive year' for phar­ma M&A. Is that a good thing?

Yesterday
Deals
Pharma

Gilead claims Tru­va­da patents in HHS’ com­plaint are in­valid

15 hours ago
Pharma

Latest

Gilead dusts off a failed Ebo­la drug as coro­n­avirus spreads; Ex­elix­is boasts pos­i­tive Ph I/II da­ta

21 hours ago
Protocols

Tri­fec­ta of sick­le cell dis­ease ther­a­pies ex­tend life ex­pectan­cy, but are not cost-ef­fec­tive — ICER

22 hours ago
Pharma

Drug-drug in­ter­ac­tions: FDA is­sues guid­ance on clin­i­cal, in vit­ro stud­ies

Yesterday
Pharma
Regulatory

Ku­ra co-founder heads to Asian mul­ti-na­tion­al as biotech eyes the goal posts for lead drug

Yesterday
People

FDA waves Epizyme's $186K rare can­cer drug through to mar­ket — now get ready for the sec­ond act

Yesterday
Pharma
Regulatory

Roche's check­point play­er Tecen­triq flops in an­oth­er blad­der can­cer sub­set

Yesterday
R&D
see latest stream
People

'Y­ou be­trayed that du­ty': For­mer con­gress­man Chris Collins sen­tenced to 26 months in jail for in­sid­er trad­ing

4 days ago

Bernie Sanders goes af­ter Bio­Mar­in's shot at a record drug price, threat­en­ing to break the patent

4 days ago

Chi­na’s fourth rich­est man takes a back seat at the top drug­mak­er he built

Last week
Startups

Mer­ck KGaA spin­out gets first fund­ing to bring dual-act­ing can­cer mol­e­cules in­to the clin­ic

Yesterday

French-Bel­gian biotech banks €20M to break ground in blood-splat­tered field of ther­a­peu­tic can­cer vac­cines

3 days ago

Boehringer, No­vo-backed Ger­man biotech banks €11M in liv­er re­gen­er­a­tion push

3 days ago
Deals

Am­gen aug­ments Asia foothold by tak­ing over Astel­las joint ven­ture in Japan

Yesterday

PureTech bags $200M from sale of Karuna shares — still siz­zling from promis­ing schiz­o­phre­nia da­ta

Yesterday

Chica­go in­vestor de­vis­es £250M deal as re­al es­tate grows with UK's biotech sec­tor

2 days ago
IPOs

Brex­it fears, Wood­ford woes over­shad­owed UK biotech and cut 2019 fi­nanc­ing by al­most half

2 days ago

First Chi­nese biotech on Nas­daq in two years draws $104M

Last week

Shoot­ing for $100M IPO, Schrödinger takes the wraps off its five in­ter­nal drugs and dis­clos­es deal de­tails

Last week

All of the news, delivered with full-text to your inbox. For professionals discovering, developing, and marketing biopharmaceutical drugs.

SUBSCRIBE NOW
Subscribe to Endpoints News

Premium storiesSee all

#JPM20 ex­clu­sive: Olivi­er Brandi­court fol­lows the Big Phar­ma CEO path to pri­vate eq­ui­ty, join­ing Black­stone ahead of ...

Last week
People
R&D

Watch live: End­points at #JPM20

Last week

Just how big is the bio­phar­ma deal­mak­ing world? In 2019 we saw mega­bil­lions in cash change hands, and that's just the ...

3 weeks ago
Deals

Here are the 52 new drugs ap­proved by the FDA in 2019. Who won? Who lost? And who just sur­vived to 2020?

4 weeks ago
Pharma
Special

Don't missSee all

UP­DAT­ED: Eli Lil­ly’s $1.6B can­cer drug failed to spark even the slight­est pos­i­tive gain for pa­tients in its 1st ...

Yesterday
R&D

The FDA has de­val­ued the gold stan­dard on R&D. And that threat­ens every­one in drug de­vel­op­ment

Yesterday
Bioregnum
Regulatory

UP­DAT­ED: New play­ers are jump­ing in­to the scram­ble to de­vel­op a vac­cine as pan­dem­ic pan­ic spreads fast

2 days ago
R&D

UP­DAT­ED: FDA’s golodirsen CRL: Sarep­ta’s Duchenne drugs are dan­ger­ous to pa­tients, of­fer­ing on­ly a small ben­e­fit. ...

3 days ago
Regulatory

Endpoints Standouts

Here are the 52 new drugs ap­proved by the FDA in 2019. Who won? Who lost? And who just sur­vived to 2020?

4 weeks ago
Pharma
Special

Spe­cial re­port: Twen­ty ex­tra­or­di­nary women in bio­phar­ma R&D who worked their way to the top

2 months ago
People
R&D

Un­lock the full End­points ex­pe­ri­ence for your com­pa­ny — and sup­port our mis­sion of in­de­pen­dent bio­phar­ma re­port­ing

Last month
Publisher's note

[Video] Cel­e­brat­ing tri­al fail­ures, chang­ing the cul­ture and al­ly­ing with Cal­i­for­nia dream­ers: R&D chief Hal Bar­ron ...

3 months ago

Peer review See all

Jan
24

Di­a­betes-fo­cused Pox­el names Eli Lil­ly vet David Moller as CSO; Ac­celeron's CBO hops ship to lead start­up

Jan
17

Pe­ter Ciriel­lo takes over the reins at Vy­gon USA; Mirum Phar­ma­ceu­ti­cals taps Ian Clements to the role of CFO

Jan
10

Eli Lil­ly vet jumps aboard Po­laris Part­ners; Mi­rati shakes up its lead­er­ship team with new hires and pro­mo­tions

Jan
3

IQVIA vet takes the helm at Chi­na's Foun­tain Med­ical; Michael Nazak pro­mot­ed to CFO post at Aridis

Dec
20

Bill Lund­berg takes over the reins at Merus; For­mer Akcea COO Jef­frey Gold­berg takes the helm of Im­mu­ni­tas

R&D channel feed

3 days ago

GSK’s ‘break­through’ BC­MA can­cer drug gets a pri­or­i­ty re­view — and a big win for the on­col­o­gy R&D team

Af­ter large­ly whiff­ing the past 2 years on the phar­ma R&D front, Glax­o­SmithK­line re­search chief Hal Bar­ron has seized boast­ing rights to a key win that puts them back in the can­cer drug ...

READ MORE

BeiGene lines up its first shot at crack­ing the megablock­buster PD-1 mar­ket for lung can­cer. But can they over­come ...

3 days ago

UP­DAT­ED: Pas­cal So­ri­ot and As­traZeneca com­mit to ze­ro-car­bon by 2025, car­bon-neu­tral by 2030. Where's the rest of ...

2 days ago
latest in R&D

Fresh tri­al da­ta for­ti­fy po­si­tion of Roche's oral ther­a­py in spinal mus­cu­lar at­ro­phy bat­tle­ground

2 days ago

Tran­si­tion­al lead­ers take charge as FDA be­gins PhI­II of OND re­or­ga­ni­za­tion

2 days ago

Io­n­is, Akcea boost­ed by a pos­i­tive PhII for their No­var­tis castoff car­dio drug — and they plan to push ahead in­to piv­otals

2 days ago

What do Mass Gen­er­al, the NCI and Mayo Clin­ic have in com­mon? They rou­tine­ly blow off an FDA rule on post­ing tri­al re­sults

3 days ago

Sci­en­tists find un­ex­pect­ed an­ti-can­cer ac­tiv­i­ty in range of non-on­col­o­gy drugs — study

4 days ago
Discovery
see latest stories

Pharma channel feed

2 days ago

Wuhan virus out­break trig­gers in­evitable small-biotech ral­ly

Every few years, a pub­lic health cri­sis (think Ebo­la, Zi­ka) spurred by a rogue pathogen trig­gers a small-biotech ral­ly, as drug­mak­ers emerge from the wood­work with am­bi­tious plans to treat ...

READ MORE

Roche cracks Chi­na's ADC mar­ket open as Kad­cy­la scores its first breast can­cer OK in the coun­try

2 days ago
China

Eli Lil­ly re­serves $470M for new man­u­fac­tur­ing plant — and North Car­oli­na is more than pleased

3 days ago
latest in Pharma

UP­DAT­ED: FDA hands off its lat­est whirl­wind drug OK as Hori­zon hus­tles would-be block­buster to the mar­ket

3 days ago
Regulatory

As­traZeneca plans to spend $535M-plus to ex­pand its R&D net­work and man­u­fac­tur­ing ops in France

3 days ago

At #JPM20, two CEOs, two rad­i­cal­ly dif­fer­ent ther­a­pies, and a fight to chase down sick­le cell

Last week
Cell/Gene Tx
R&D

GSK, Pfiz­er con­tra­dict on the fu­ture of con­sumer health JV — re­port

Last week

War­ren and Klobuchar say they can low­er drug prices with­out Con­gress’ help

Last week
People
see latest stories